Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥543.69K ≈ $79.56K USD) by net assets (CN¥1.15 Billion ≈ $168.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Suzhou Zelgen Biopharmaceuticals Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Suzhou Zelgen Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Suzhou Zelgen Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check total reinvestment intensity of Suzhou Zelgen Biopharmaceuticals Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Suzhou Zelgen Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SLM Corp
NASDAQ:SLM
|
-0.031x |
|
Seaboard Corporation
NYSE MKT:SEB
|
-0.010x |
|
Alaska Air Group Inc
NYSE:ALK
|
0.113x |
|
Jinneng Holding Shanxi Coal Industry Co Ltd
SHG:601001
|
0.030x |
|
Geovis Technology Co Ltd
SHG:688568
|
0.020x |
|
Ningbo Joyson Electronic Corp
SHG:600699
|
0.074x |
|
SentinelOne Inc
NYSE:S
|
0.003x |
|
Texas Capital Bancshares, Inc.
NASDAQ:TCBI
|
0.024x |
Annual Cash Flow Conversion Efficiency for Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Suzhou Zelgen Biopharmaceuticals Co Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.25 Billion ≈ $183.29 Million |
CN¥38.20 Million ≈ $5.59 Million |
0.031x | +122.77% |
| 2023-12-31 | CN¥1.64 Billion ≈ $240.69 Million |
CN¥-220.31 Million ≈ $-32.24 Million |
-0.134x | +71.52% |
| 2022-12-31 | CN¥787.49 Million ≈ $115.23 Million |
CN¥-370.34 Million ≈ $-54.19 Million |
-0.470x | -29.62% |
| 2021-12-31 | CN¥1.25 Billion ≈ $183.37 Million |
CN¥-454.62 Million ≈ $-66.53 Million |
-0.363x | -78.48% |
| 2020-12-31 | CN¥1.69 Billion ≈ $247.53 Million |
CN¥-343.86 Million ≈ $-50.32 Million |
-0.203x | +91.69% |
| 2019-12-31 | CN¥73.75 Million ≈ $10.79 Million |
CN¥-180.43 Million ≈ $-26.40 Million |
-2.446x | -512.81% |
| 2018-12-31 | CN¥281.64 Million ≈ $41.21 Million |
CN¥-112.44 Million ≈ $-16.45 Million |
-0.399x | +73.07% |
| 2017-12-31 | CN¥73.02 Million ≈ $10.69 Million |
CN¥-108.25 Million ≈ $-15.84 Million |
-1.482x | -186.02% |
| 2016-12-31 | CN¥109.44 Million ≈ $16.01 Million |
CN¥-56.72 Million ≈ $-8.30 Million |
-0.518x | -- |
About Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate … Read more